INDOCO REMEDIES LTD.
INDOCO · General/Diversified · NSE
₹206
Current Market Price
Fair Value (DCF)
₹95
Margin of Safety
-54.1%
Updated 2d ago
YieldIQ Score
21/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
5%
ROE
—
Debt/Equity
1.03
WACC
11.1%
Market Cap
₹1,902 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
30.1×
Enterprise multiple
Debt / EBITDA
10.1×
Leverage vs earnings
Interest Coverage
-0.2×
EBIT covers interest
Current Ratio
1.24×
Short-term liquidity
Asset Turnover
0.68×
Revenue per ₹ of assets
Revenue CAGR (3Y)
3.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹206.34
Bear case
₹0
MoS -Infinity%
Base case
₹94.71
MoS -117.9%
Bull case
₹99.45
MoS -107.5%
Ratio Trends
INDOCO · last 8 annual periods
ROE
-7.2%
ROCE
5.0%
Operating Margin
—
Debt / Equity
0.98×
PE
21.1×
EV / EBITDA
11.0×
Historical Financials
INDOCO · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1242 Cr | ₹1541 Cr | ₹1640 Cr | ₹1788 Cr | ₹1641 Cr | +7.2% |
| EBITDA | — | ₹330 Cr | ₹287 Cr | ₹263 Cr | ₹101 Cr | -25.5% |
| EBIT | ₹154 Cr | ₹251 Cr | ₹47.6 Cr | ₹45.0 Cr | — | -26.5% |
| PAT | ₹93.0 Cr | ₹155 Cr | ₹142 Cr | ₹98.5 Cr | ₹-73.7 Cr | — |
| EPS (diluted) | ₹10.10 | ₹16.80 | ₹2.80 | ₹2.39 | — | -30.3% |
| CFO | ₹82.2 Cr | ₹174 Cr | ₹179 Cr | ₹157 Cr | ₹94.9 Cr | +3.7% |
| CapEx | — | — | — | — | ₹-356 Cr | — |
| FCF | — | — | — | — | ₹-261 Cr | — |
| Total Assets | — | ₹1486 Cr | ₹1658 Cr | ₹2145 Cr | ₹2430 Cr | +13.1% |
| Total Debt | — | — | ₹174 Cr | ₹308 Cr | ₹994 Cr | +54.5% |
| Shareholders' Equity | — | — | ₹1028 Cr | ₹1110 Cr | ₹1018 Cr | -0.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INDOCO vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| WINDLAS WINDLAS | — | — | Pending | 12.1% | — |
| MOREPENLAB MOREPENLAB | — | — | Pending | 9.9% | — |
| HIKAL HIKAL | — | — | Pending | 7.2% | — |
| SOLARA SOLARA | — | — | Pending | 0.0% | — |
| UNICHEMLAB UNICHEM LABORATORIES LTD | +28.6% | 56 | Below Fair Value | 5.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for INDOCO in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of INDOCO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INDOCO →
Compare
Head-to-head with peers
Compare INDOCO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INDOCONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.